





Use Signatera[™] to inform risk-based adjuvant treatment selection and monitor immunotherapy response

Signatera[™] ctDNA-positive patients had a 10x higher risk of recurrence than ctDNA-negative patients¹



- > ctDNA-positivity was associated with significantly shorter DMFS (HR=10.77; p=0.01)
- Outcomes were improved in ctDNA-positive patients who were treated with adjuvant ICI
- 📎 ctDNA-positivity at week 6 of adjuvant ICI therapy was significantly associated with an inferior DMFS (HR: 34.54, P<0.0001)

On-treatment ctDNA dynamics were significantly associated with DMFS¹



who converted to or were persistently ctDNA positive

> Signatera[™] provided a lead time to recurrence of 3 months vs. standard imaging



Use Signatera[™] ctDNA dynamics to inform earlier treatment decisions in metastatic melanoma patients

Early on-treatment ctDNA dynamics were predictive of PFS in metastatic melanoma patients receiving 1st line ICI treatment¹

At week 6, Signatera™ identified that patients with increasing ctDNA had a 18x higher risk of progression than ctDNA-negative patients



> Patients with any increase in ctDNA levels from baseline by week 6 of 1st Line ICI treatment (monotherapy and combination ICIs) had a significantly shorter PFS (HR: 18; p=0.013).

> Signatera[™] was able to help distinguish between true vs pseudo-progression

Should treatment be changed or escalated?

Early rise in ctDNA can help inform treatment escalation or change



60-year-old stage IV metastatic melanoma patient²

Adapted from a real-world Signatera[™] patient case. Case features modified to protect patient confidentiality. No treatment recommendations are made or should be implied.



Learn more at www.natera.com/signateraskincancers-clinicians

Covered by Medicare for immunotherapy treatment response monitoring across all stages for solid tumors

PFS = Progression-free survival

References:

- 1. Eroglu Z, Krinshpun S, Kalashnikova E, et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer (2023). https://doi.org/10.1002/cncr.34716
- Eroglu Z, Krinshpun S, Martin J, et al. Molecular residual disease detection and circulating tumor DNA dynamics during treatment in patients with advanced melanoma. Abstract presented at: 10th World Congress of Melanoma; April 15-17, 2021; virtual meeting. #P-096. https://worldmelanoma2021.com/

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

Signatera has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2023 Natera, Inc. All Rights Reserved. SGN_MD_OS_Melanoma_20230405_NAT-9300002



 $\mathbf{X} \mathbf{X} \mathbf{X} \mathbf{X}$

× × × × × × × ×